Noorik Biopharmaceuticals AG
Clinical-stage biopharmaceutical company based in Basel, Switzerland focused on repurposing and developing micro-dose formulations of an endothelin receptor antagonist for indications affecting vascular dysfunction (severe COVID-19 respiratory failure, portal hypertension in liver cirrhosis, and complications of solid-organ transplantation). The company performs clinical trials, develops low-dose oral and parenteral formulations, manages regulatory strategy for re‑submission, and seeks co-development partners.
Industries
Nr. of Employees
small (1-50)
Noorik Biopharmaceuticals AG
Patents
Products
N-003 (micro-dose ambrisentan) — investigational product
An investigational micro-dose formulation of an endothelin receptor antagonist developed for oral and parenteral administration to selectively modulate ETA receptor activity at lower plasma concentrations.
N-003 (micro-dose ambrisentan) — investigational product
An investigational micro-dose formulation of an endothelin receptor antagonist developed for oral and parenteral administration to selectively modulate ETA receptor activity at lower plasma concentrations.
Services
Engagement with prospective partners to co-develop micro-dose formulations through technical and clinical development into commercialization.
Engagement with prospective partners to co-develop micro-dose formulations through technical and clinical development into commercialization.
Expertise Areas
- Clinical trial management
- Drug repurposing (small molecules)
- Formulation development (oral and parenteral)
- Pulmonary vascular disease and acute pulmonary hypertension
Key Technologies
- Endothelin receptor antagonism
- Micro-dosing of small-molecule therapeutics
- Oral and parenteral formulation development
- Randomized placebo-controlled clinical trials
News & Updates
Signing of a development contract under the Federal Funding Programme for COVID-19 Medicines to support accelerated clinical development of micro-dose ambrisentan (press release dated December 13, 2021).
A Phase II study in patients with liver cirrhosis and portal hypertension was recently completed and reported by the company as having promising results.
Contract and funding awarded to support development of micro-dose ambrisentan for Severe COVID-19 under a federal program.
Signing of a development contract under the Federal Funding Programme for COVID-19 Medicines to support accelerated clinical development of micro-dose ambrisentan (press release dated December 13, 2021).
A Phase II study in patients with liver cirrhosis and portal hypertension was recently completed and reported by the company as having promising results.
Contract and funding awarded to support development of micro-dose ambrisentan for Severe COVID-19 under a federal program.